This study will continue to evaluate the efficacy of naltrexone as an adjunct to treatment for alcohol dependence. Findings from our 12-week, double blind study comparing 50 mg. per day of naltrexone or placebo in 70 male alcoholics in outpatient rehabilitation provides support for the efficacy of naltrexone revealing that relative to subjects receiving placebo tablets, the naltrexone group reported less alcohol craving, fewer days in which alcohol was consumed, fewer days of intoxication, and had lower liver enzyme tests and much lower rates of alcohol relapse. The proposed study constitutes a more comprehensive, large scale extension of our earlier research using a heterogeneous population of men and women. Specifically, we will assess for what subgroups of alcoholics and for what duration of treatment is naltrexone an effective adjunct. Thus, one hundred-eighty alcohol dependent rehabilitation outpatients will be randonly assigned to either adjunctive naltrexone for three months, naltrexone for nine months, or to a placebo treatment in a double blind design extending over a nine month period. The larger N in this study, in addition to providing sufficient power necessary for the determination of group differences, will also permit subgroup analyses. A secondary aim of this study will be to attempt to determine whether there are psychiatric subgroups of patients that are particularly helped by naltrexone. Recent evidence suggests that alcohol dependent patients with significant psychopathology may have a worse prognosis than non-psychiatrically impaired patients. Preliminary data from our first study supports this observation with relatively high relapse rates in so called """"""""dual-diagnosis """""""" patients. In contrast, naltrexone treated subjects had a remarkably low relapse rate in this subgroup.
A final aim of this study will begin to study the mechanism of action of naltrexone. Animal research suggests that naltrexone may decrease alcohol drinking because of its pharmacological effects of blocking opiate receptors. Preliminary data, from our initial study shows that among subjects who slip, that is have any alcohol during the twelve week active medication phase, naltrexone significantly blocks the high from alcohol. Based on our preliminary data, we hypothesize that naltrexone will block the pleasurable effects of alcohol and reduce craving only in those subgroups of subjects who sample alcohol.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA007517-05
Application #
3111245
Study Section
Clinical and Treatment Subcommittee (ALCP)
Project Start
1989-04-01
Project End
1997-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Drapkin, Michelle L; Yusko, David; Yasinski, Carly et al. (2011) Baseline functioning among individuals with posttraumatic stress disorder and alcohol dependence. J Subst Abuse Treat 41:186-92
Plebani, Jennifer G; Tirado, Carlos F; Pettinati, Helen M et al. (2010) Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict Behav 35:123-8
Kim, Sung-Gon; Han, Byeung-Deuk; Park, Je-Min et al. (2004) Effect of the combination of naltrexone and acamprosate on alcohol intake in mice. Psychiatry Clin Neurosci 58:30-6
Pettinati, Helen M; Monterosso, John; Lipkin, Craig et al. (2003) Patient attitudes toward treatment predict attendance in clinical pharmacotherapy trials of alcohol and drug treatment. Am J Addict 12:324-35
Rukstalis, Margaret R; Lynch, Kevin G; Oslin, David W et al. (2002) Carbohydrate-deficient transferrin levels reflect heavy drinking in alcohol-dependent women seeking treatment. Alcohol Clin Exp Res 26:1539-44
Monterosso, J R; Flannery, B A; Pettinati, H M et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258-68
Volpicelli, J R (2001) Alcohol abuse and alcoholism: an overview. J Clin Psychiatry 62 Suppl 20:4-10
Weinrieb, R M; Van Horn, D H; McLellan, A T et al. (2001) Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis 20:105-19
Kim, S G; Stromberg, M F; Kim, M J et al. (2000) The effect of antagonists selective for mu- and delta-opioid receptor subtypes on alcohol consumption in C57BL/6 mice. Alcohol 22:85-90
Rukstalis, M R; Stromberg, M F; O'Brien, C P et al. (2000) 6-beta-naltrexol reduces alcohol consumption in rats. Alcohol Clin Exp Res 24:1593-6

Showing the most recent 10 out of 14 publications